NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$225.40

-3.01 (-1.32%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $225.17
▼
$230.00
50-Day Range: $224.46
▼
$253.15
52-Week Range: $198.64
▼
$258.45

Volume: 2.54 million shs
Average Volume: 2.59 million shs
Market Capitalization: $120.57 billion

P/E Ratio: 19.10
Dividend Yield: 3.40%
Price Target: $242.64

Amgen MarketRank™ Forecast

Analyst Rating: Hold
2.14 Rating Score
Upside/Downside: 7.6% Upside
$242.64 Price Target
Short Interest: Bearish
3.18% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.42
Upright™ Environmental Score
News Sentiment: 0.61
Based on 9 Articles This Week
Insider Trading: Selling Shares
$1.69 M Sold Last Quarter
Proj. Earnings Growth: 9.46%
From $17.45 to $19.10 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

180th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

25th out of 171 stocks

2.1

Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 4 buy ratings, 8 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $242.64, Amgen has a forecasted upside of 7.6% from its current price of $225.40.
Amount of Analyst Coverage
Amgen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
3.18% of the float of Amgen has been sold short.
Short Interest Ratio / Days to Cover
Amgen has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Amgen has recently increased by 2.60%, indicating that investor sentiment is decreasing.

4.2

Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 3.40%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has been increasing its dividend for 10 years.
Dividend Coverage
The dividend payout ratio of Amgen is 65.76%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 40.63% next year. This indicates that Amgen will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.
Environmental Sustainability
The Environmental Impact score for Amgen is -2.42.

1.5

News and Social Media Coverage

News Sentiment
Amgen has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Amgen this week, compared to 14 articles on an average week.
Search Interest
Only 38 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
MarketBeat Follows
Only 29 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,693,392.00 in company stock.
Percentage Held by Insiders
Only 0.46% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
77.14% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 9.46% in the coming year, from $17.45 to $19.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 19.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 19.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.60.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 18.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

October 1, 2022 | finance.yahoo.com

Amgen Inc. (NASDAQ:AMGN) Looks Just Right

September 29, 2022 | stocknews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

September 28, 2022 | finance.yahoo.com

3 Biotech Stocks to Buy and Hold for the Next 10 Years

September 28, 2022 | finance.yahoo.com

Amgen and Bristol-Myers- Healthy Values - Yahoo Finance

September 27, 2022 | businesswire.com

Global Gastroesophageal Cancer Market Research Report to 2027 - Featuring Amgen, Bayer and Bristol Myers Squibb Among Others - ResearchAndMarkets.com - Business Wire

September 27, 2022 | finance.yahoo.com

Amgen Inc. (NASDAQ:AMGN) insiders sold US$4.9m worth of stock suggesting impending weakness.

September 23, 2022 | finance.yahoo.com

Amgen (NASDAQ:AMGN) shareholders have earned a 7.3% CAGR over the last five years

September 21, 2022 | reuters.com

Biden Administration asks Supreme Court to reject Amgen's Repatha patent appeal - Reuters

September 21, 2022 | finance.yahoo.com

Amgen (AMGN) Stock Moves -1.43%: What You Should Know

September 21, 2022 | nasdaq.com

EU approves AstraZeneca-Amgen treatment for severe asthma - Nasdaq

September 21, 2022 | seekingalpha.com

Amgen, AstraZeneca's Tezspire for severe asthma gets approval in EU - Seeking Alpha

September 20, 2022 | nasdaq.com

Is Amgen (NASDAQ:AMGN) Using Too Much Debt? - Nasdaq

September 19, 2022 | finance.yahoo.com

Amgen's (NASDAQ:AMGN) five-year total shareholder returns outpace the underlying earnings growth

September 16, 2022 | nasdaq.com

Amgen (AMGN) Stock Moves -0.2%: What You Should Know - Nasdaq

September 15, 2022 | marketwatch.com

: Amgen’s new cancer drug faces questions about competition

September 15, 2022 | seekingalpha.com

Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer (NASDAQ:AMGN) - Seeking Alpha

September 14, 2022 | bloomberg.com

Amgen CEO on New Products, M&A, Drug Pricing Legislation - Bloomberg

September 14, 2022 | stocknews.com

The Worst Biotech Stock to Own in September

September 14, 2022 | 247wallst.com

Wednesday Upgrades Downgrades: Amgen, AppLovin, Blue Owl Capital, Dell Technologies, Dow, Marvell Technology, PayPal, RingCentral, Shopify, SoFi Technologies, Twilio, Western Digital, WiPro, Wolfspeed - 24/7 Wall St.

September 13, 2022 | seekingalpha.com

Amgen drops to six-month low amid latest challenges to pipeline

September 13, 2022 | seekingalpha.com

Amgen Inc. (AMGN) Management Presents at Morgan Stanley's 2022 Global Healthcare Conference (Transcript) - Seeking Alpha

September 13, 2022 | benzinga.com

Amgen (NASDAQ:AMGN) – Here's Why Amgen Shares Are Diving - Benzinga

September 12, 2022 | stocknews.com

2 Biotech Stocks Defying the Bear Market and 1 That's Not

September 12, 2022 | cnbc.com

Stocks making the biggest moves midday: Bristol-Myers Squibb, Twitter, Gilead Sciences and more - CNBC

September 12, 2022 | finance.yahoo.com

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Last Earnings: 8/04/2022
Ex-Dividend for 9/8 Dividend: 8/17/2022
Dividend Payable: 9/08/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:AMGN
CUSIP: 03116210
CIK: 318154
Web: www.amgen.com
Phone: (805) 447-1000
Fax: 805-447-1010
Employees: 24,200
Year Founded: 1980

Price Target and Rating

Average Stock Price Forecast: $242.64
High Stock Price Forecast: $290.00
Low Stock Price Forecast: $182.00
Forecasted Upside/Downside: +7.6%
Consensus Rating: Hold
Rating Score (0-4): 2.14
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $11.80
Trailing P/E Ratio: 19.10
Forward P/E Ratio: 12.92
P/E Growth: 1.84
Net Income: $5.89 billion
Net Margins: 24.92%
Pretax Margin: 28.40%
Return on Equity: 218.34%
Return on Assets: 16.29%

Debt

Debt-to-Equity Ratio: 14.76
Current Ratio: 1.53
Quick Ratio: 1.17

Sales & Book Value

Annual Sales: $25.98 billion
Price / Sales: 4.64
Cash Flow: $23.33 per share
Price / Cash Flow: 9.66
Book Value: $12.00 per share
Price / Book: 18.78

Miscellaneous

Outstanding Shares: 534,930,000
Free Float: 532,470,000
Market Cap: $120.57 billion
Optionable: Optionable
Beta: 0.56

Social Links

Key Executives

Mr. Robert A. Bradway (Age 59)
Chairman, CEO & Pres
Comp: $5.81M

Mr. Peter H. Griffith (Age 63)
Exec. VP & CFO
Comp: $2.66M

Mr. Esteban Santos (Age 54)
Exec. VP of Operations
Comp: $2.61M

Dr. David M. Reese M.D. (Age 59)
Exec. VP of R&D
Comp: $2.79M

Mr. Murdo Gordon (Age 55)
Exec. VP of Global Commercial Operations
Comp: $2.82M

Ms. Linda H. Louie
VP of Fin. & Chief Accounting Officer

Mr. Mike Zahigian
Sr. VP & Chief Information Officer

Mr. Arvind Sood
VP of Investor Relations

Mr. Jonathan P. Graham (Age 61)
Exec. VP, Gen. Counsel & Sec.

Ms. Nancy A. Grygiel (Age 54)
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.
What is Amgen's stock price forecast for 2022?: 14 brokers have issued 1-year target prices for Amgen's stock. Their AMGN share price forecasts range from $182.00 to $290.00. On average, they predict the company's stock price to reach $242.64 in the next year. This suggests a possible upside of 7.6% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.
How have AMGN shares performed in 2022?: Amgen's stock was trading at $224.97 at the beginning of 2022. Since then, AMGN shares have increased by 0.2% and is now trading at $225.40.
View the best growth stocks for 2022 here.
When is Amgen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMGN earnings forecast.
How were Amgen's earnings last quarter?: Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Thursday, August, 4th. The medical research company reported $4.65 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.25. The medical research company earned $6.59 billion during the quarter, compared to analysts' expectations of $6.53 billion. Amgen had a trailing twelve-month return on equity of 218.34% and a net margin of 24.92%. The business's revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the business posted $4.38 earnings per share.
Read the conference call transcript.
How often does Amgen pay dividends? What is the dividend yield for Amgen?: Amgen declared a quarterly dividend on Wednesday, August 3rd. Shareholders of record on Thursday, August 18th will be paid a dividend of $1.94 per share on Thursday, September 8th. This represents a $7.76 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date is Wednesday, August 17th.
Read our dividend analysis for AMGN.
Is Amgen a good dividend stock?: Amgen (NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.40%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 65.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 40.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.
What guidance has Amgen issued on next quarter's earnings?: Amgen issued an update on its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share (EPS) guidance of $17.00-$18.00 for the period, compared to the consensus estimate of $17.40. The company issued revenue guidance of $25.50 billion-$26.40 billion, compared to the consensus revenue estimate of $26.23 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?: 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.
What other stocks do shareholders of Amgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).
What is Amgen's stock symbol?: Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How do I buy shares of Amgen?: Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amgen's stock price today?: One share of AMGN stock can currently be purchased for approximately $225.40.
How much money does Amgen make?: Amgen (NASDAQ:AMGN) has a market capitalization of $120.57 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $11.80 on an earnings per share basis.
How many employees does Amgen have?: The company employs 24,200 workers across the globe.
Does Amgen have any subsidiaries?: The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?: Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amgen - AMGN Stock Forecast, Price & News

Amgen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows